Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study
This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.
Inclusion criteria
Exclusion criteria
clinicaltrials@novonordisk.com(+1) 866-867-7178
Szeged, Csongrád-Csanád 6725, Hungary
Chiba-shi, Chiba, 260-0804, Japan
Bialystok, Podlaskie Voivodeship 15-351, Poland
Coimbra, 3000-150, Portugal
Ponte de Lima, 4990-029, Portugal
Vila do Conde, 4480-565, Portugal
Vila Nova de Gaia, 4400-346, Portugal
Yangsan, Gyeongsangnam-do 50612, South Korea
La Roca Del Vallés, Barcelona 08430, Spain